Technical Analysis for BCYC - Bicycle Therapeutics plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 22.19 | 1.23% | 0.27 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
Doji - Bearish? | Reversal | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 1.23% | |
Calm After Storm | Range Contraction | 1.23% |
Alert | Time |
---|---|
Rose Above 20 DMA | 1 day ago |
10 DMA Resistance | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
50 DMA Resistance | 1 day ago |
Rose Above 10 DMA | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.9 |
52 Week Low | 12.54 |
Average Volume | 390,178 |
200-Day Moving Average | 20.17 |
50-Day Moving Average | 23.10 |
20-Day Moving Average | 22.58 |
10-Day Moving Average | 22.15 |
Average True Range | 1.37 |
RSI (14) | 46.81 |
ADX | 18.54 |
+DI | 33.28 |
-DI | 18.45 |
Chandelier Exit (Long, 3 ATRs) | 22.66 |
Chandelier Exit (Short, 3 ATRs) | 25.09 |
Upper Bollinger Bands | 24.28 |
Lower Bollinger Band | 20.87 |
Percent B (%b) | 0.39 |
BandWidth | 15.10 |
MACD Line | -0.26 |
MACD Signal Line | -0.26 |
MACD Histogram | 0.0002 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 25.45 | ||||
Resistance 3 (R3) | 25.69 | 24.84 | 24.90 | ||
Resistance 2 (R2) | 24.84 | 24.01 | 24.72 | 24.72 | |
Resistance 1 (R1) | 23.52 | 23.50 | 24.18 | 23.28 | 24.54 |
Pivot Point | 22.67 | 22.67 | 23.01 | 22.55 | 22.67 |
Support 1 (S1) | 21.35 | 21.84 | 22.01 | 21.11 | 19.84 |
Support 2 (S2) | 20.50 | 21.33 | 20.38 | 19.66 | |
Support 3 (S3) | 19.18 | 20.50 | 19.48 | ||
Support 4 (S4) | 18.94 |